Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH +0.26%65 Cash Ratio is 2.11 as of Jun. 2026, which is 43% below its 10-year median of 3.68. GuruFocus rates SOPH with a GF Score™ of 65/100 and a GF Value™ of $5.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Sophia Genetics ranks better than 81.08% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Sophia Genetics Cash Ratio Related Terms
Sophia Genetics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a Cash Ratio of 2.11 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sophia Genetics and its competitors. This is 43% below median its historical median of 3.68. Over the past decade, Sophia Genetics' Cash Ratio has ranged from 0.96 to 10.11. According to the industry distribution chart, Sophia Genetics ranks #126 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 18.9%.
Is Sophia Genetics' Cash Ratio too high?
Sophia Genetics' current Cash Ratio of 2.11 is 43% below median its 10-year median of 3.68. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 10.11. The Healthcare Providers & Services industry median Cash Ratio is 0.58. Sophia Genetics' value of 2.11 is 263.8% above this industry median. Based on the distribution chart, Sophia Genetics ranks #126 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sophia Genetics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Cash Ratio compare to EVH and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #126 out of 666 companies for Cash Ratio. This places Sophia Genetics in the top 19% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.58. Sophia Genetics' value of 2.11 is 263.8% above this benchmark. Historically, Sophia Genetics' own Cash Ratio has ranged from 0.96 to 10.11 over the past decade. While the company's 10-year median is 3.68 vs. the industry median of 0.58, Sophia Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Cash Ratio of 2.11 is 263.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Cash Ratio is 2.11, which is 43% below median its own 10-year median of 3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.10, compared to a current price of $7.58 — trading 48.6% above its estimated fair value. The current Cash Ratio is 2.11, which is 43% below median its 10-year median of 3.68 and 263.8% above the Healthcare Providers & Services industry median of 0.58. Sophia Genetics' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Cash Ratio is 2.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $7.58 is trading 48.6% above its estimated GF Value™ of $5.10.
GuruFocus considers Sophia Genetics to be Significantly Overvalued.
Key valuation signals for SOPH:
Cash Ratio: 2.11 (43% below median its 10-year median of 3.68)
GF Value™: $5.10 vs. price of $7.58 (48.6% above fair value)
Industry Position: 263.8% above the Healthcare Providers & Services median (#126 of 666)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
65GF Score
Get the complete analysis for SOPH
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
